- Home
- Publications
- Publication Search
- Publication Details
Title
Mirk/dyrk1B kinase is upregulated following inhibition of mTOR
Authors
Keywords
-
Journal
CARCINOGENESIS
Volume 35, Issue 9, Pages 1968-1976
Publisher
Oxford University Press (OUP)
Online
2014-03-04
DOI
10.1093/carcin/bgu058
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Abstract 2165: Structure activity relationship of a novel chemical class of Dyrk inhibitors.
- (2014) Anne-Sophie Casagrande et al. CANCER RESEARCH
- Identifying MicroRNA and mRNA Expression Profiles in Embryonic Stem Cells Derived from Parthenogenetic, Androgenetic and Fertilized Blastocysts
- (2013) Xiang-Shun Cui et al. Journal of Genetics and Genomics
- Different Patterns of Akt and ERK Feedback Activation in Response to Rapamycin, Active-Site mTOR Inhibitors and Metformin in Pancreatic Cancer Cells
- (2013) Heloisa P. Soares et al. PLoS One
- Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
- (2012) Taru Muranen et al. CANCER CELL
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition
- (2012) Jing Hu et al. INTERNATIONAL JOURNAL OF CANCER
- Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR) Inhibitors and Characterization of Their Binding Kinetics
- (2012) Qingsong Liu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer
- (2012) C. P. Carden et al. MOLECULAR CANCER THERAPEUTICS
- IKBKE Protein Activates Akt Independent of Phosphatidylinositol 3-Kinase/PDK1/mTORC2 and the Pleckstrin Homology Domain to Sustain Malignant Transformation
- (2011) Jian-Ping Guo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Inactivation of Mirk/Dyrk1b Kinase Targets Quiescent Pancreatic Cancer Cells
- (2011) D. Z. Ewton et al. MOLECULAR CANCER THERAPEUTICS
- Rapamycin passes the torch: a new generation of mTOR inhibitors
- (2011) Don Benjamin et al. NATURE REVIEWS DRUG DISCOVERY
- Transient arrest in a quiescent state allows ovarian cancer cells to survive suboptimal growth conditions and is mediated by both Mirk/dyrk1b and p130/Rb2
- (2010) Jing Hu et al. INTERNATIONAL JOURNAL OF CANCER
- The PI3K Pathway As Drug Target in Human Cancer
- (2010) Kevin D. Courtney et al. JOURNAL OF CLINICAL ONCOLOGY
- mTOR: from growth signal integration to cancer, diabetes and ageing
- (2010) Roberto Zoncu et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Mirk/Dyrk1B Maintains the Viability of Quiescent Pancreatic Cancer Cells by Reducing Levels of Reactive Oxygen Species
- (2009) X. Deng et al. CANCER RESEARCH
- Cancer Stem Cells and Aneuploid Populations within Developing Tumors Are the Major Determinants of Tumor Dormancy
- (2009) A. P. Kusumbe et al. CANCER RESEARCH
- Insulin Receptor Substrate-2 Mediated Insulin-like Growth Factor-I Receptor Overexpression in Pancreatic Adenocarcinoma through Protein Kinase Cδ
- (2009) Junhye Kwon et al. CANCER RESEARCH
- TORC-Specific Phosphorylation of Mammalian Target of Rapamycin (mTOR): Phospho-Ser2481 Is a Marker for Intact mTOR Signaling Complex 2
- (2009) J. Copp et al. CANCER RESEARCH
- The kinase Mirk is a potential therapeutic target in osteosarcoma
- (2009) C. Yang et al. CARCINOGENESIS
- Targeting the PI3K signaling pathway in cancer
- (2009) Kwok-Kin Wong et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Mirk Regulates the Exit of Colon Cancer Cells from Quiescence
- (2009) Kideok Jin et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
- (2009) A. C. Faber et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma
- (2008) Tim F Cloughesy et al. PLOS MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started